Interviews

Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses venetoclax (Venclexta) for the treatment of elderly patients with chronic lymphocytic leukemia (CLL). 

Brian Van Tine, MD, PhD, assistant professor, Washington University School of Medicine, discusses the development of olaratumab (Lartruvo) in soft tissue sarcoma.

Ajai Chari, MD, associate professor, Mount Sinai Hospital, discusses some of the recent clinical trial evidence for early relapsed multiple myeloma and how it can be put into practice.

Kanti R. Rai, MD, professor, The Karches Center for Oncology Research, The Feinstein Institute for Medical Research, director, Center for Oncology and Cell Biology, Long Island Jewish Medical Center, professor, Medicine and Molecular Medicine, Hofstra Northwell School of Medicine, discusses optimal treatment sequencing for patients with chronic lymphocytic leukemia (CLL).

John Mascarenhas, MD, associate professor, Icahn School of Medicine at Mount Sinai, discusses the role of <em>JAK2</em> inhibition in patients with polycythemia vera (PV).

Maurie Markman, MD, president of medicine and science, Cancer Treatment Centers of America, discusses valuable endpoints beyond overall survival (OS) that can be used in ovarian cancer clinical trials.

Cathy Eng, MD, FACP, professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses choosing between TAS-102 (Lonsurf) and regorafenib (Stivarga) in colorectal cancer.

John L. Marshall, MD, Director, The Ruesch Center for the Cure of Gastrointestinal Cancers&nbsp;at Georgetown Lombardi Comprehensive Cancer Center, discusses decision making in the frontline treatment of patients with metastatic colon cancer.

Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses ovarian suppression and bone cancer management in breast cancer.

Victoria Atkinson, MD, medical oncologist, Princess Alexandra Hospital, University of Queensland, discusses combination regimens on the horizon in melanoma.

Eileen O&rsquo;Reilly, MD, associate director for clinical research at Memorial Sloan Kettering Cancer Center, discusses new developments in pancreatic cancer care.

Richard S. Finn, MD, assistant professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California, Los Angeles, discusses&nbsp;advances in the development of CDK4/6 inhibitors for the treatment of hormone receptor (HR)-positive breast cancer. &nbsp; &nbsp;

Justin F. Gainor, MD, medical oncologist, Assistant Professor of Medicine, Massachusetts General Hospital, Harvard Medical School, discusses how the treatment paradigm for EGFR+ lung cancer will transform over the next several years.

Anne Chiang, MD, PhD, professor and thoracic oncologist at Yale Cancer Center, discusses the future of treatment for oligometastatic lung cancer.

Maurie Markman, MD, president of medicine and science, Cancer Treatment Centers of America, discusses overall survival as an endpoint in ovarian cancer.

Natalie S. Callander, MD, Professor of Medicine, University of Wisconsin Carbone Cancer Center, discusses updates in the treatment of relapsed/refractory multiple myeloma.

Vancheswaran Gopalakrishnan, MPH, a post-doctorate fellow in Dr. Jennifer Wargo&#39;s laboratory at The University of Texas MD Anderson Cancer Center, discusses a study that explored the diversity and composition of the gut microbiome in melanoma patients and its influence on response to anti-PD-1 therapy&nbsp;during The Society for Immunotherapy of Cancer (SITC) 32nd&nbsp;Annual Meeting. Dr.&nbsp;Gopalakrishnan completed this study under the mentorship of Dr. Wargo, who was the principal investigator.&nbsp;

Vinod P. Balachandran, MD, Surgical Oncologist, Memorial Sloan Kettering Cancer Center, discusses an analysis to determine the unique antigen qualities of long-term survivors of pancreatic cancer&nbsp;during The Society for Immunotherapy of Cancer (SITC) 32nd&nbsp;Annual Meeting.

Owen O&#39;Connor, MD, PhD, professor of medicine and Experimental Therapeutics, director of the Center for Lymphoid Malignancies, Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, discusses the agents approved by the FDA for the treatment of mantle cell lymphoma (MCL), including acalabrutinib (Calquence) and bortezomib (Velcade).

Ralf Huss, MD, Chief Medical Officer of Definiens, discusses a new immuno-oncology panel introduced by Definiens during the The Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting. The goal of the panel is to standardize the immunoprofiling of tumors to better predict response to immuno-oncology treatment.

Matthew D. Galsky, MD, Professor of Medicine, Mount Sinai School of Medicine, discusses progression in patients with metastatic bladder cancer.

Kelly Paulson, MD, PhD, a fellow at Seattle Cancer Care Alliance, discusses single-cell RNA sequencing in merkel cell carcinoma during&nbsp;The Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting.

Johanna C. Bendell, MD, director of GI Oncology Research at Sarah Cannon Research Institute, discusses using immunotherapy for the treatment of patients with colorectal cancer.

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, UC Davis Health System, discusses results of the ALEX clinical trial, which compared alectinib (Alecensa) versus crizotinib (Xalkori) in patients with ALK+&nbsp;non&ndash;small cell lung cancer (NSCLC).

Ruben Mesa, MD, director, UT Health San Antonio Cancer Center, discusses NCCN guideline updates in polycythemia vera and essential thrombocythemia.

Jason Luke, MD, assistant professor of medicine, University of Chicago Medicine, discusses the promising combination of a PD-1 antibody plus an IDO inhibitor for the treatment of patients with melanoma.<br /> &nbsp;

Massimo Cristofanilli, MD, professor of medicine, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, discusses overcoming resistance to endocrine therapy in ER+ breast cancer.

Jennifer Chan, MD, MPH, clinical director, Program in Carcinoid and Neuroendocrine Tumors, Dana-Farber Cancer Institute, discusses a study exploring cabozantinib (Cabometyx) for the treatment of patients with advanced carcinoid and pancreatic neuroendocrine tumors.

Matthew Kulke, MD, director, Neuroendocrine and Carcinoid Tumors Program, Dana-Farber Cancer Institute, discusses treatment options on the horizon in the treatment of neuroendocrine tumors (NETs) during the 2017 NANETS Symposium.

Sandy Wong, MD, assistant professor, Division of Hematology/Oncology, UCSF School of Medicine, discusses the progress that has been made with monocloncal antibodies for the treatment of plasma cell neoplasms.